mTOR Inhibitor Conversion After a Second Skin Cancer
A second skin cancer in eighteen months makes the cancer-recurrence case for conversion, and early calcineurin-inhibitor injury makes the renal case for it too — but the same conversion trials that support both arguments also show real harm when the timing is wrong.
Carla J. is sixty-one, and thirty-eight years of landscaping work — most of it bare-armed, most of it without much thought given to sunscreen until a dermatologist finally made her start — have left her fair skin carrying more sun damage than her six years since transplant alone would explain. She had a basal cell carcinoma removed from her cheek eighteen months ago, and last month a second lesion, this one a squamous cell carcinoma on her forearm, came back from pathology with clear margins but no reassurance about what a third excision site might look like next year.
Her transplant course has otherwise been ordinary until recently: a routine biopsy done to work up a slowly rising creatinine, prompted by nothing more than a monitoring protocol rather than any acute event, showed early arteriolar changes consistent with calcineurin-inhibitor toxicity — not advanced, not yet fibrotic in the way a longer-standing injury looks, but real and named on the pathology report. Her current eGFR sits at 51, and her urine protein-creatinine ratio, checked the same visit, is 0.3 — and read against CONVERT's own subgroup thresholds those two numbers point in opposite directions rather than sitting together near a line. CONVERT stratified on a baseline GFR of 40, halting its own 20-to-40 arm early for excess harm after conversion; at 51 she is clearly on the safe side of that. But the favorable subgroup it identified required a urine protein-creatinine ratio of 0.11 or less, and hers is nearly three times that. She is not a borderline case on one axis; she is comfortably inside the trial's benefiting population on filtration and well outside it on protein.
Her dermatologist, who caught both lesions early enough that neither needed anything beyond local excision, has been the one pushing hardest for a conversation with the transplant team about her immunosuppression itself rather than treating each new spot as an isolated surgical problem. Two cancers in eighteen months is, in her dermatologist's own words, "a pattern, not bad luck" — the kind of statement that carries real weight precisely because it comes from someone who has watched her skin closely enough to notice the interval shortening, not just the count rising.
Combined transplant-dermatology clinic
She's already past the point the trial evidence addresses directly — the TUMORAPA trial found sirolimus conversion after a first post-transplant skin cancer reduced recurrence, and she's had a second cancer in eighteen months. I'd convert now rather than wait for a third lesion to make an already-strong case even stronger. Her skin cancer trajectory alone is reason enough.
I'd want to slow down before converting her this week specifically. mTOR inhibitors carry a real, well-documented burden — impaired wound healing, mouth ulcers, edema, and new or worsened proteinuria — and she has a forearm incision that had its sutures out only a week ago. Starting a drug known to delay wound healing right at that site, right now, risks a real complication for a marginal timing gain.
I'm not arguing against conversion in principle — the cancer-recurrence case is real. I'm arguing the timing matters, and a few weeks' delay to let that wound fully close costs her very little against the actual risk of starting today.
Timing aside, I don't think either of you has actually checked her against the number that matters most. CONVERT's post-hoc subgroup — baseline GFR above 40 and a urine protein-creatinine ratio of 0.11 or less — is the population that actually did better after conversion; its 20-to-40 GFR stratum was stopped early for excess safety events. Her eGFR of 51 clears the first criterion without difficulty. Her UPCR of 0.3 misses the second by roughly threefold, and proteinuria is the variable that predicted trouble, not filtration. So she isn't borderline — she splits the two criteria, and she splits them on the axis mTOR inhibitors make worse.
Because the proteinuria is the part that disqualifies her, I'd favor a combination approach — reduced-dose tacrolimus alongside low-dose sirolimus, rather than a full switch — which the same trial's data suggest tolerates better in patients near that threshold than an all-or-nothing conversion. That also buys the wound-healing delay the pharmacist wants, since a lower starting mTOR dose is a gentler introduction either way.
Agreed: a combination low-dose sirolimus/reduced-tacrolimus regimen rather than a full switch, with sirolimus start delayed three weeks to allow the forearm incision to fully close. The physician's threshold-based framing — checking her actual eGFR and proteinuria against the conversion trial's own subgroup data — was accepted by both other voices as the deciding criterion, ahead of either the cancer-recurrence argument alone or the wound-healing concern alone.
Not agreed: how aggressively to pursue full conversion later if her renal numbers hold stable or improve on the combination regimen. The dermatologist wants to revisit full conversion at six months given the ongoing skin cancer risk; the pharmacist would rather hold the combination indefinitely once it's tolerated, seeing no clear reason to push further once the wound-healing and renal-threshold concerns that shaped today's decision have both been addressed.